FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. PMID 42135177 · Eur Urol · 2026-May-15 The study is an original, randomized trial in oncology with a time-to-event endpoint, but it compares two surgical techniques (non-drug intervention) and does not meet the required Phase III/IIIb or Phase II/III evidence criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site. PMID 41935492 · Eur J Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. PMID 41921365 · Eur J Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629). PMID 41905242 · Eur J Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. PMID 41779000 · Clin Cancer Res · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment. PMID 41671078 · Clin Cancer Res · 2026-May-15 The report is an original randomized trial, but the abstract focuses on a secondary/prognostic biomarker analysis (ctDNA) rather than the primary efficacy comparison of the intervention. The required phase (III/IIIb or II/III) is not explicitly established in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results. PMID 41632450 · Clin Cancer Res · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). PMID 41609523 · Clin Cancer Res · 2026-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Markers in umbilical cord blood in early-onset fetal growth restricted fetuses. PMID 42215002 · Placenta · 2026-May-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study. PMID 42150214 · Breast · 2026-May-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Investigation of oral bromelain supplementation on the healing of skin flap reconstruction after Mohs micrographic surgery (MMS) for non-melanoma skin cancers (NMSCs). PMID 42135693 · BMC Surg · 2026-May-14 The study is a randomized trial in an oncology context (non-melanoma skin cancer) with a drug/intervention (bromelain), but the primary endpoint is time to suture removal, which is a wound-healing measure, not a standard oncological time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer. PMID 42134900 · J Immunother Cancer · 2026-May-14 The study is an observational analysis using real-world data to emulate a randomized trial, not a prospective Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention as defined by the criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| HIV and Substance Use Reduction for Youth Experiencing Homelessness: Development and Usability Study. PMID 42133932 · JMIR Form Res · 2026-May-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis. PMID 42133432 · Clin J Am Soc Nephrol · 2026-May-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial. PMID 42127391 · N Engl J Med · 2026-May-14 The study is a Phase III randomized trial of a drug (telitacicept) in humans, but it is not an oncology study; it evaluates IgA nephropathy. Furthermore, the primary endpoint is a surrogate biomarker (proteinuria reduction), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. |
H
L
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts. PMID 42127390 · N Engl J Med · 2026-May-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Trial of Brepocitinib in Dermatomyositis. PMID 41910335 · N Engl J Med · 2026-May-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study. PMID 42129213 · Nat Commun · 2026-May-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Does laser treatment affect outcome in pilonidal sinus disease? Long-term multicenter retrospective analysis of pit-picking alone vs. pit-picking with laser. PMID 42128975 · Tech Coloproctol · 2026-May-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity? PMID 42128519 · J Immunother Cancer · 2026-May-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). PMID 42128502 · BMJ Open · 2026-May-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial. PMID 42128454 · BMJ · 2026-May-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life comparing standard and prolonged time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer: results from the multicenter, randomized, controlled NeoRes II trial. PMID 42132923 · Dis Esophagus · 2026-May-12 The study is a randomized, controlled trial in oncology (esophageal cancer) but is a secondary/quality-of-life analysis. It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc., or Kaplan-Meier/HR for such endpoints). Furthermore, the intervention is a timing comparison (standard vs. prolonged time-to-surgery) and not a drug-containing intervention; the neoadjuvant chemoradiotherapy is part of the standard of care for all patients, not a variable being tested. The abstract explicitly states the primary endpoints have been reported previously, and this report is a sub-study focused on quality of life. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial. PMID 42121244 · Trials · 2026-May-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial. PMID 42119607 · J Natl Compr Canc Netw · 2026-May-12 The study is a randomized Phase III trial with a drug intervention (hydromorphone vs. morphine) in oncology patients. However, the primary efficacy endpoint is pain relief measured by the Numeric Rating Scale (NRS), which is not a time-to-event outcome (e.g., OS, PFS, DFS). No Kaplan-Meier curves or hazard ratios for time-to-event endpoints are reported. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial. PMID 42119606 · J Natl Compr Canc Netw · 2026-May-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Risk-Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta-Analysis. PMID 42117884 · Int J Cancer · 2026-May-12 The record is a systematic review and meta-analysis comparing phase 2 and phase 3 trials, not an original report of a single randomized trial. It does not meet the criteria for a drug-containing intervention trial with a primary/key secondary time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial. PMID 42117295 · BJU Int · 2026-May-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cardioprotective effects of platycodon grandiflorum granules in HER2-positive early breast cancer patients receiving trastuzumab plus pertuzumab: study protocol for a double blind randomized controlled trial. PMID 42116119 · BMC Complement Med Ther · 2026-May-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial. PMID 41984450 · JAMA · 2026-May-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension. PMID 41670573 · J Am Coll Cardiol · 2026-May-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial. PMID 42219932 · JMIR Res Protoc · 2026-May-11 The record is a protocol for a randomized trial but does not report original results and uses a non-time-to-event primary endpoint. It is excluded as a protocol-without-results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Encounter tool for Shared Decision Making about Adjuvant Treatment of Lung Cancer: Randomized Clinical Trial. PMID 42183367 · Res Sq · 2026-May-11 The record describes a planned randomized trial protocol for evaluating a shared decision-making tool, not a report of trial results. It lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The phase is not definitively established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L. PMID 42119729 · J Thorac Oncol · 2026-May-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate-to-Severe Endometriosis Pain: A Phase III, Multicentric, Double-Blind, Active-Controlled, Non-Inferiority Study. PMID 42116589 · BJOG · 2026-May-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of digital exercise therapy and cognitive behavioral therapy on body image and social distance of postoperative patients with breast cancer: study protocol for a randomized controlled trial. PMID 42116180 · Trials · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Involved nodal versus elective neck radiotherapy (INVERT) for head and neck squamous cell carcinoma: a prospective phase II randomized controlled trial protocol. PMID 42116021 · BMC Cancer · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. PMID 42114950 · J Immunother Cancer · 2026-May-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial. PMID 42114858 · BMJ Open · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Optimising a behavioural intervention to support endocrine therapy adherence for women with breast cancer: protocol for the ROSETA optimisation factorial randomised controlled trial. PMID 42108483 · Trials · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial. PMID 42108589 · Neuro Oncol · 2026-May-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. PMID 41894648 · J Clin Oncol · 2026-May-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments. PMID 42192882 · Cancers (Basel) · 2026-May-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 2 trial. PMID 42114123 · J Sex Med · 2026-May-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Suicidal Ideation Effectiveness and Safety Outcomes from the Ketamine for Adult Depression Study (KADS). PMID 42105367 · Arch Suicide Res · 2026-May-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intraoperative biodegradable stent placement to reduce complications after pancreatoduodenectomy - interim results from a randomised clinical trial. PMID 42104174 · Langenbecks Arch Surg · 2026-May-09 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial. PMID 42102826 · Lancet · 2026-May-09 The study is a randomized, Phase III trial in oncology with original results, but it is excluded because it does not involve a drug-containing intervention (colonoscopy is a screening procedure) and does not have a primary or key secondary time-to-event efficacy endpoint (outcomes are cumulative incidence and mortality risk ratios, not time-to-event analyses like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR is reported). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial. PMID 42026952 · JNCI Cancer Spectr · 2026-May-09 The study is a randomized controlled trial (RCT) embedded within a genomic diagnostics trial for prostate cancer, but it is not a drug-intervention trial. It compares treatment patterns (secondary treatment rates and time to treatment) between trial participants and real-world cohorts, but the intervention is a genomic classifier, not a drug. The time-to-event endpoint is time to secondary treatment, but this is not a standard efficacy endpoint (e.g., OS, PFS, DFS) for a drug-containing intervention. The phase is not established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain. PMID 42192875 · Cancers (Basel) · 2026-May-08 The record describes a meta-analysis and pooled analysis of placebo response rates in multiple trials, not the primary results of a single Phase III randomized trial with a time-to-event efficacy endpoint. The study focuses on symptom outcomes (neuropathy response rates) and does not report OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The convenience of contrast-enhanced intraoperative ultrasonic cholangiography in liver resection: a study protocol for a randomized, prospective, off-label trial. PMID 42104300 · BMC Surg · 2026-May-08 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |